The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Illarioshkin S.N.

Research Center of Neurology

Litvinenko I.V.

Kirov Military Medical Academy

Mkhitaryan E.A.

Pirogov Russian National Research Medical University;
Russian Clinical and Research Center of Gerontology Pirogov — Russian National Research Medical University

Pizova N.V.

Yaroslavl State Medical University

Yakupov E.Z.

JCL «Your Health»

Diagnosis and treatment of early forms of cognitive impairment: possibilities of influencing neuronal energy metabolism. Resolution of the Council of Experts

Authors:

Bogolepova A.N., Zaharov V.V., Illarioshkin S.N., Litvinenko I.V., Mkhitaryan E.A., Pizova N.V., Yakupov E.Z.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9): 131‑140

DOI: 10.17116/jnevro2023123091131

Read: 4996 times

Download PDF (RU)
Contact the author
Table of contents

DIAGNOSIS AND TREATMENT OF EARLY FORMS OF COGNITIVE IMPAIRMENT: POSSIBILITIES OF INFLUENCING NEURONAL ENERGY METABOLISM. RESOLUTION OF THE COUNCIL OF EXPERTS
DIAGNOSIS AND TREATMENT OF EARLY FORMS OF COGNITIVE IMPAIRMENT: POSSIBILITIES OF INFLUENCING NEURONAL ENERGY METABOLISM. RESOLUTION OF THE COUNCIL OF EXPERTS

To cite this article:

Bogolepova AN, Zaharov VV, Illarioshkin SN, Litvinenko IV, Mkhitaryan EA, Pizova NV, Yakupov EZ. Diagnosis and treatment of early forms of cognitive impairment: possibilities of influencing neuronal energy metabolism. Resolution of the Council of Experts. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9):131‑140. (In Russ.)
https://doi.org/10.17116/jnevro2023123091131

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Diagnosis and treatment of early forms of cognitive impairment: possibilities of influencing neuronal energy metabolism. Resolution of the Council of Experts.

Authors:

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Illarioshkin S.N.

Research Center of Neurology

Litvinenko I.V.

Kirov Military Medical Academy

Mkhitaryan E.A.

Pirogov Russian National Research Medical University;
Russian Clinical and Research Center of Gerontology Pirogov — Russian National Research Medical University

Pizova N.V.

Yaroslavl State Medical University

Yakupov E.Z.

JCL «Your Health»

Received:

16.08.2023

Accepted:

22.08.2023

Close metadata

References:

  1. Bacigalupo I, Mayer F, Lacorte E, et al. A Systematic Review and Meta-Analysis on the Prevalence of Dementia in Europe: Estimates from the Highest-Quality Studies Adopting the DSM IV Diagnostic Criteria. J Alzheimers Dis. 2018;66:1471-1481. https://doi.org/10.3233/JAD-180416
  2. Vorobyeva NM, Khovasova NO, Tkacheva ON, et al. Falls and fractures in subjects over 65 years old and their associations with geriatric syndromes: Russian epidemiological study EVKALIPT. Russian Journal of Gerontilogy. 2019;23(7):34-39. (In Russ.).
  3. Pereira ML, de Vasconcelos THF, de Oliveira AAR, et al. Memory complaints at primary care in a middle-income country: clinical and neuropsychological characterization. Dement Neuropsychol. 2021;15:88-97.  https://doi.org/10.1590/1980-57642021dn15-010009
  4. Boustani M, Callahan CM, Unverzagt FW, et al. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med. 2005;20:572-577. 
  5. Fowler NR, Perkins AJ, Turchan HA, et al. Older primary care patients’ attitudes and willingness to screen for dementia. J Aging Res. 2015;2015:423265. https://doi.org/10.1155/2015/423265
  6. McCarten JR, Rottunda SJ, Kuskowski MA. Change in the mini-mental state exam in Alzheimer’s disease over 2 years: the experience of a dementia clinic. J Alz Dis. 2004;6:11-15.  https://doi.org/10.3233/jad-2004-6102
  7. Calvin CM, Wilkinson T, Starr JM, et al. Predicting incident dementia 3-8 years after brief cognitive tests in the UK Biobank prospective study of 500,000 people. Alzheimers Dement. 2019;15:1546-1557. https://doi.org/10.1016/j.jalz.2019.07.014
  8. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153. https://doi.org/10.1212/wnl.56.9.1143
  9. Yakhno NN, Zakharov VV, Lokshina AB. Memory and attention disorders in old age. Jurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2006;106(7):58-62. (In Russ.).
  10. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.  https://doi.org/10.1001/archneur.56.3.303
  11. Lindsay J, Sykes E, McDowell I, et al. More than the epidemiology of Alzheimer’s disease: contributions of the Canadian Study of Health and Aging. Can J Psychiatry. 2004;49:83-91.  https://doi.org/10.1177/070674370404900202
  12. Di Carlo A, Lamassa M, Baldereschi M, et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology. 2007;68:1909-1916. https://doi.org/10.1212/01.wnl.0000263132.99055.0d
  13. Zakharov VV. Nationwide research program on the epidemiology and treatment of cognitive disorders in old age («Prometheus»). Nevrologicheskii Zhurnal. 2006;11:27-32. (In Russ.).
  14. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 2013.
  15. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844-852.  https://doi.org/10.1016/j.jalz.2014.01.001
  16. Rabin LA, Smart CM, Crane PK, et al. Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. J Alzheimers Dis. 2015;48(suppl 1):63-86.  https://doi.org/10.3233/JAD-150154
  17. Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry. 2018;33:379-388.  https://doi.org/10.1002/gps.4756
  18. de Gage SB, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345(32):45-49. 
  19. Urry LA, Cain ML, Wasserman SA, et al. Campbell biology. Pearson Education, Incorporated; 2017.
  20. Lodish H, Berk A, Kaiser CA, et al. Mol Cell Biol. 2006;34(32):44-48. 
  21. Thyagarajan D. Mitochondrial disease. Neurol Ther Princ Pract. Ed JH Noseworthy Second Ed Abingdon Inf Healthc. 2006;2:152. 
  22. Aronov DM. What a practicing physician needs to know about ubiquinone (coenzyme Q10). Russkii Meditsinskii Zhurnal. 2006;14:223-230. (In Russ.).
  23. Saric A, Andreau K, Armand A-S, et al.Barth syndrome: from mitochondrial dysfunctions associated with aberrant production of reactive oxygen species to pluripotent stem cell studies. Front Genet. 2016;6:359. 
  24. Lei D, Shao Z, Zhou X, Yuan H. Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. Oncotarget. 2018;9:12137.
  25. Voronkova KV, Meleshkov MN. The use of noben (idebenone) in the therapy of dementia and memory disorders not reaching the stage of dementia. Zhurnal Nevrologii i Psikhiatrii im S.S. Korsakova. 2008;108(7):27-32. (In Russ.).
  26. Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013;9:657-665.  https://doi.org/10.1016/j.jalz.2012.09.012
  27. Zhu X, Yin S, Lang M, et al. The more the better? A meta-analysis on effects of combined cognitive and physical intervention on cognition in healthy older adults. Ageing Res Rev. 2016;31:67-79.  https://doi.org/10.1016/j.arr.2016.07.003
  28. Nagaoka A, Kakihana M, Fujiwara K. Effects of idebenone on neurological deficits following cerebrovascular lesions in stroke-prone spontaneously hypertensive rats. Arch Gerontol Geriatr. 1989;8:203-212.  https://doi.org/10.1016/0167-4943(89)90003-4
  29. Suno M, Nagaoka A. Inhibition of brain mitochondrial swelling by idebenone. Arch Gerontol Geriatr. 1989;8:299-305.  https://doi.org/10.1016/0167-4943(89)90011-3
  30. Gillis JC, Benefield P, McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging. 1994;5:133-152.  https://doi.org/10.2165/00002512-199405020-00007
  31. Nappi G, Bono G, Merlo P, et al. Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. Arch Gerontol Geriatr. 1992;15:261-269.  https://doi.org/10.1016/0167-4943(92)90061-8
  32. Lingetti M, Porfido FA, Ciarimboli M, et al. Evaluation of the clinical efficacy of idebenone in patients affected by chronic cerebrovascular disorders. Arch Gerontol Geriatr. 1992;15:225-237.  https://doi.org/10.1016/0167-4943(92)90058-c
  33. Fustinoni O, Abiusi G, Mut A, et al. Effect of idebenone on the outcome of completed stroke. In: XVI World Congress of Neurology. Abstracts. Buenos-Aires 1997;1:7:38. 
  34. Beard GM. Stimulants and narcotics: medically, philosophically, and morally considered. GP Putnam; 1971.
  35. Brurberg KG, Fønhus MS, Larun L, et al. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open. 2014;4:e003973. https://doi.org/10.1136/bmjopen-2013-003973
  36. Clayton EW. Redefining Myalgic Encephalomyelitis/Chronic Fatigue Syndrome — Reply. JAMA. 2015;314:85-86.  https://doi.org/10.1001/jama.2015.5760
  37. Bakken IJ, Tveito K, Gunnes N, et al. Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008—2012. BMC Med. 2014;12:1-7. 
  38. Faro M, Sàez-Francás N, Castro-Marrero J, et al. Gender differences in chronic fatigue syndrome. Reumatol Clínica (English Ed.) 2016;12:72-77. 
  39. Teodoro T, Edwards MJ, Isaacs JD. A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review. J Neurol Neurosurg Psychiatry. 2018;89:1308-1319. https://doi.org/10.1136/jnnp-2017-317823
  40. Bansal AS, Bradley AS, Bishop KN, et al. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun. 2012;26:24-31.  https://doi.org/10.1016/j.bbi.2011.06.016
  41. Noor N, Urits I, Degueure A, et al. A Comprehensive Update of the Current Understanding of Chronic Fatigue Syndrome. Anesthesiol Pain Med. 2021;11:e113629. https://doi.org/10.5812/aapm.113629
  42. Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med. 1985;102:7-16.  https://doi.org/10.7326/0003-4819-102-1-7
  43. Ablashi D V, Eastman HB, Owen CB, et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol. 2000;16:179-191.  https://doi.org/10.1016/s1386-6532(99)00079-7
  44. Buchwald D, Garrity D, Pascualy R, et al. Chronic fatigue syndrome. Toxicol Ind Health. 1992;8:157-173. 
  45. Martin WJ. Detection of RNA sequences in cultures of a stealth virus isolated from the cerebrospinal fluid of a health care worker with chronic fatigue syndrome. Case report. Pathobiology. 1997;65:57-60.  https://doi.org/10.1159/000164104
  46. McGarry F, Gow J, Behan PO. Enterovirus in the chronic fatigue syndrome. Ann Intern Med. 1994;120:972-973.  https://doi.org/10.7326/0003-4819-120-11-199406010-00020
  47. Holmes MJ, Diack DS, Easingwood RA, et al. Electron microscopic immunocytological profiles in chronic fatigue syndrome. J Psychiatr Res. 1997;31:115-122.  https://doi.org/10.1016/s0022-3956(96)00048-9
  48. Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome and/or fibromyalgia syndrome. Eur J Clin Microbiol Infect Dis. 1999;18:859-865.  https://doi.org/10.1007/s100960050420
  49. Rasa S, Nora-Krukle Z, Henning N, et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. 2018;16:268.  https://doi.org/10.1186/s12967-018-1644-y
  50. Biswal B, Kunwar P, Natelson BH. Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. J Neurol Sci. 2011;301:9-11. 
  51. Mathew SJ, Mao X, Keegan KA, et al. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 2009;22:251-258.  https://doi.org/10.1002/nbm.1315
  52. Jerjes WK, Taylor NF, Wood PJ, Cleare AJ. Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome. Psychoneuroendocrinology. 2007;32:192-198.  https://doi.org/10.1016/j.psyneuen.2006.12.005
  53. Tang SW, Chu E, Hui T, et al. Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects. Neurosci Lett. 2008;431:62-65. 
  54. Katafuchi T, Kondo T, Take S, Yoshimura M. Brain cytokines and the 5-HT system during poly I:C-induced fatigue. Ann N Y Acad Sci. 2006;1088:230-237.  https://doi.org/10.1196/annals.1366.020
  55. Rostene W, Kitabgi P, Parsadaniantz SM. Chemokines: a new class of neuromodulator? Nat Rev Neurosci. 2007;8:895-903. 
  56. Komaroff AL, Cho TA. Role of infection and neurologic dysfunction in chronic fatigue syndrome. Semin Neurol. 2011;31:325-37. 
  57. Moroz IN, Podkolzin AA. New developments in the diagnosis and treatment of chronic fatigue syndrome. Profilaktika Stareniya. 1999;1:45-47. (In Russ.).
  58. Sotzny F, Blanco J, Capelli E, et al. Myalgic encephalomyelitis/chronic fatigue syndrome-evidence for an autoimmune disease. Autoimmun Rev. 2018;17:601-609. 
  59. Wilson CG, Ramage M, Fagan EB. A Primary Care Response to COVID‐19 for Patients with an Opioid Use Disorder. J Rural Heal. 2021;37:169-171. 
  60. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:1-7. 
  61. Lam MH-B, Wing Y-K, Yu MW-M, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169:2142-2147.
  62. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15:e0240784.
  63. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. SSRN. 2021;3820561.
  64. Kedor C, Freitag H, Meyer-Arndt L-A, et al. Chronic COVID-19 Syndrome and Chronic Fatigue Syndrome (ME/CFS) following the first pandemic wave in Germany: a first analysis of a prospective observational study. MedRxiv. 2021. https://doi.org/10.1101/2021.02.06.21249256
  65. Sandler CX, Wyller VBB, Moss-Morris R, Buchwald D, Crawley E, Hautvast J, et al. Long COVID and post-infective fatigue syndrome: A review. Infect Dis. 2021;8:440-450. 
  66. Pennington C, Newson M, Hayre A, Coulthard E. Functional cognitive disorder: what is it and what to do about it? Pract Neurol. 2015;15:436-444.  https://doi.org/10.1136/practneurol-2015-001127
  67. Schmaling KB, Betterton KL. Neurocognitive complaints and functional status among patients with chronic fatigue syndrome and fibromyalgia. Int J Qual Life. 2016;25:1257-1263. https://doi.org/10.1007/s11136-015-1160-y
  68. McDonald E, Cope H, David A. Cognitive impairment in patients with chronic fatigue: a preliminary study. J Neurol Neurosurg Psychiatry. 1993;56:812-815.  https://doi.org/10.1136/jnnp.56.7.812
  69. Katz RS, Heard AR, Mills M, Leavitt F. The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. J Clin Rheumatol. 2004;10:53-58.  https://doi.org/10.1097/01.rhu.0000120895.20623.9f
  70. Deluca J, Christodoulou C, Diamond BJ, et al. Working memory deficits in chronic fatigue syndrome: differentiating between speed and accuracy of information processing. J Int Neuropsychol Soc. 2004;10:101-109.  https://doi.org/10.1017/S1355617704101124
  71. Sandman CA, Barron JL, Nackoul K, Goldstein J, Fidler F. Memory deficits associated with chronic fatigue immune dysfunction syndrome. Biol Psychiatry. 1993;33:618-623.  https://doi.org/10.1016/0006-3223(93)90100-r
  72. Neu D, Kajosch H, Peigneux P, et al. Cognitive impairment in fatigue and sleepiness associated conditions. Psychiatry Res. 2011;189:128-134. 
  73. Constant EL, Adam S, Gillain B, et al. Cognitive deficits in patients with chronic fatigue syndrome compared to those with major depressive disorder and healthy controls. Clin Neurol Neurosurg. 2011;113:295-302.  https://doi.org/10.1016/j.clineuro.2010.12.002
  74. Cortes-Rivera M, Mastronardi C, Silva-Aldana CT, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics. 2019;9:91. 
  75. Richman S, Morris MC, Broderick G, et al. Pharmaceutical Interventions in Chronic Fatigue Syndrome: A Literature-based Commentary. Clin Ther. 2019;41:798-805.  https://doi.org/10.1016/j.clinthera.2019.02.011
  76. Montenegro L, Turnaturi R, Parenti C, Pasquinucci L. Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy. Nanomater. 2018;8:45-49.  https://doi.org/10.3390/nano8020087
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.